A Study recently published in the journal The Lancet Infectious Diseases indicates that overuse of fluoroquinolones may be sole cause of deadly C. Diff Epidemic. Antibiotic overuse can have severe consequences, especially with certain types of antibiotics and this study begins to quantify one of the ways in which this happens and how widespread the harm […]
On January 23, 2017 the national health service of Canada, Health Canada, announced that their recent safety review revealed serious safety issues with fluoroquinolone antibiotics. This follows the 2015 review conducted by the U.S Food & Drug Administration which reached a similar conclusion. The FDA review results were announced on 5/12/2016. In addition to […]
Pulmaquin, an inhaled liposomal ciprofloxacin, is currently undergoing two Phase 3 clinical studies to determine its safety and effectiveness as an inhaled formulation for the treatment of patients with non-cystic fibrosis bronchiectasis, cystic fibrosis or non-tuberculous mycobacteria.
Changing the Tide of Antibiotic-Resistant Infections
The Quinolone Vigilance Foundation wishes to thank all of our supporters. We had a busy and productive year and we would not be able to do this kind of work without all of our supporters. The Year in Review is posted on our Facebook page: https://www.facebook.com/notes/quinolone-vigilance-foundation/2016-year-in-review/1332337300118474
The Quinolone Vigilance Foundation testified at the FDA and made a presentation on behalf of QVF and the USA Patient Network at the FDA Meeting on Off Label Uses of drugs and devices.
Many patients are given prescription drugs and devices for uses that are not approved by the FDA (called “off label”) without informed […]
Melinta Therapeutics Submits Baxdela (delafloxacin) New Drug Application for Hospital-Treated Skin Infections
Melinta Therapeutics announced on October 24, 2016 that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for approval of IV and oral Baxdela™ (delafloxacin) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).
Melinta Therapeutics Press Release
WRIC-TV airs news story about QVF’s Dear Healthcare Provider letter campaign. QVF Executive Director Rachel Brummert and QVF Ambassador Jonathan Furman sat down with WRIC-TV investigative reporter Kerri O’Brien on October 13.
The Quinolone Vigilance Foundation has been working for several months on a new research initiative, and finalized it on October 13, 2016. QVF is partnering with a major university to collect and analyze quinolone related data. We are not naming the university at this time to protect the integrity of the project. Once the […]
The Quinolone Vigilance Foundation and Progressive Medical Center have collaborated to produce and release a short educational video about issues surrounding quinolone antibiotics.
Part one (2:59 mins)-
Part two (4:38 mins)-
We have some news to share with everyone.
It would be preferable if the FDA were more effective in communicating emerging information about drug safety issues. Sadly, the FDA never sent out Dear Doctor letters on the recent acknowledgement of fluoroquinolone risks, and despite working to try to get the FDA to send them, the […]